Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic-pharmacodynamic model for patients with haemophilia A.

ABSTRACT:

Aims

Prophylactic treatment of haemophilia A patients with factor VIII (FVIII) concentrate focuses on maintaining a minimal trough FVIII activity level to prevent bleeding. However, due to differences in bleeding tendency, the pharmacokinetic (PK)-guided dosing approach may be suboptimal. An alternative approach could be the addition of haemostatic pharmacodynamic (PD) parameters, reflecting a patient's unique haemostatic balance. Our aim was to develop a population PK/PD model, based on FVIII activity levels and Nijmegen Haemostasis Assay (NHA) patterns, a global haemostatic assay that measures thrombin/plasmin generation simultaneously.

Methods

PK/PD measurements were collected from 30 patients treated with standard half-life FVIII concentrate. The relationship between FVI

SUBMITTER: Bukkems LH 

PROVIDER: S-EPMC9304184 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature